Japan’s FY2024 pharmaceutical sales revealed a sharp divergence among immune checkpoint inhibitors as MSD’s Keytruda (pembrolizumab) surged toward the 200-billion-yen…
HOME > BUSINESS
BUSINESS
- Eisai to Forge Cross-Regional Biz Units for Oncology, Neurology in July
March 11, 2014
- Otsuka, UCB Japan File Partial Change Application for Monotherapy for E Keppra
March 11, 2014
- Ethical Drug Sales Up 4.7% in January Owing to Growth in Influenza-Related Products: Crecon Report
March 11, 2014
- Takeda Picks Third-Party Investigator for CASE-J Issue, Probe Expected to Take 3 Months
March 11, 2014
- Pfizer Japan Logs 1.2% Sales Increase in FY2013
March 10, 2014
- Eisai, Biogen Idec to Jointly Develop, Commercialize AD Treatments
March 10, 2014
- Asahi Kasei Pharma Exec Hori Picked as Next President
March 10, 2014
- Takeda Submits NDA for Once-Weekly DPP-4 Inhibitor Trelagliptin
March 10, 2014
- US Journal to Revise COI Disclosure in Article Used by Shionogi and Eli Lilly Japan to Promote Cymbalta
March 10, 2014
- 28% of Mainstays to Face New Price Cuts for Long-Listed Drugs: Jiho Survey
March 7, 2014
- Map Software Used to Reorganize MRs’ Marketing Territories Boosts Operating Efficiency at Pfizer Japan
March 7, 2014
- Five Generic Makers See Various Price Reduction Rates under FY2014 NHI Revision
March 6, 2014
- New Price Cuts for Long-Listed Drugs to Pummel MTPC, Astellas: Jiho Tally
March 6, 2014
- Santen Licenses Anti-Endoglin Antibodies from TRACON to Develop Novel Treatments for Retinal Diseases
March 6, 2014
- Samsca Tops January “Mind Share” Ranking in HP Market
March 5, 2014
- Eylea Filed for Diabetic Macular Edema in Japan: Bayer HealthCare
March 5, 2014
- Takeda Extended 3.7 Billion Yen in CASE-J-Linked Grants to Kyoto Univ., 2 Entities; “No COI” Says Pres. Hasegawa
March 4, 2014
- Takeda Apologizes for Violating Promotion Code, Inappropriate Expressions in Ads
March 4, 2014
- DSP Transfers Marketing Rights for Inteban, Catlep, and Drenison to Teikoku Seiyaku
March 4, 2014
- Astellas Secures Exclusive Rights for Isavuconazole in US, Canada
March 4, 2014
ページ
I recently attended a fantastic conference hosted by Prospection Japan, and one speaker, Dr. Joe Ledsam, really blew me away with his insights. He shared some truly fascinating developments about how AI is set to revolutionize healthcare, from how doctors…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…